Recurrent incomplete central retinal vein occlusion in a patient with hereditary thrombophilia;Ponavljajuća nepotpuna okluzija centralne retinalne vene u pacijenta s hereditarnom trombofilijom

Acta Medica Croatica

Volumn 60, Issue 2, 2006, Pages 171-174

  Duić, Jasna ^a   Gverić Krečak, Velka ^b  

^a Odjel za Neurokirurgiju   (Croatia)

^b Biokemijsko Hematolo ki Laboratorij   (Croatia)

Author keywords

Central retinal vein occlusion; Factor V Leiden; Hereditary thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; BLOOD CLOTTING FACTOR 5; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING TEST; CASE REPORT; CENTRAL RETINA VEIN OCCLUSION; COLOR ULTRASOUND FLOWMETRY; DNA DETERMINATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; SEROLOGY; THROMBOPHILIA; BLOOD; GENETICS; MUTATION; RECURRENT DISEASE; RETINA VEIN OCCLUSION;

ADULT; FACTOR V; FEMALE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECURRENCE; RETINAL VEIN OCCLUSION; THROMBOPHILIA;

EID: 33748451149     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Progr Retin Eye Res 2005; 24: 493-519.
2. Lahey JM, Kearney JJ, Tunc M. Hypercoagulable states and central retinal vein occlusion. Curr Opin Pulm Med 2003; 9: 385-92.
3. Larsson J, Hultberg B, Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand 2000; 78: 340-3.
4. Kuhli C, Scharrer I, Koch F, Ohrloff C, Hattenbach LO. Factor XII deficiency: thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol God?? ; 137: str. od-do.
5. Nachman RL, Silverstein R. Hypercoagulable states. Am Fam Physician 1997; 56: 1591-6.
6. Harris JM, Abramson N. Evaluation of reccurrent thrombosis and hypercoagulability. Am Fam Physician 2001; vol?? 591-6.
7. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126: 638-44.
8. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367-73.
9. Endler G, Mannhalter C. Polymorphism in coagulation genes and their impact on arterial and venous thrombosis. Clin Chim Acta 2003; 330: 31-55.
10. Vine AK, Samama MM. Screening for resistance to activated protein C and the mutant gene factor V: Q506 in patients with central vein occlusion. Am J Ophthalmol 1997; 124: 673-6.
11. Loewenstein A, Winder A, Goldstein M i sur. Bilateral retinal vein occlusion associated with 5, 10-methylentetrahydrofolate reductase mutation. Am J Ophthalmol 1997; 124: 840-1.
12. Incorvaia C, Bandello F, Bandello F, Parmeggiani F, D'Angelo S, Costagliola C, Sebastiani A. Recurrent central vein occlusion in a young thrombopholic patient with factor V Leiden mutation. Eur J Ophthalmol 2002; 12: 131-4.
13. Federici C, Gianetti J, Andreassi MG. Genomic medicine and thrombotic risk: who, when, how and why? Int J Cardiol 2005, u tisku.
14. Labar B, Hauptmann E i sur. Hematologija. Zagreb: Školska knjiga, 1998, 198-9.
15. Larsson J, Olafsdottir E, Bauer B. Activted protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80: 200-2.
16. Williamson TH. Central retinal vein occlusion: what's the story? Br J Ophthalmol 1997; 81: 687-704.
17. Glueck CJ, Bell H, Vadlamani L i sur. Heritable thrombophilia an hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43-9.
18. Chak M, Wallace GR, Graham EM, Stanford MR. Thrombophilia genetic polymorphism and their association with retinal vascular occlusive disase. Br J Ophthalmol 2001; 85: 883-6.
19. Glueck CJ, Wang P, Bell H, Rangaraj V, Goldenbeerg N. Associations of thrombophilia, hypofibrinolysis, and retinal vein occlusion. Clin Appl Thrombosis Hemostasis 2005; 11: 375-89.
20. Delahousse AS, Regina BG, Le Lez S, Pisella MI, Grue PJ. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 year of age. Thromb Haemos 2005; 94: 101-6.
21. Cruciani F, Moramarco A, Curto T i sur. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risk factors for youth retinal vein occlusion. Clin Ter 2003; 154: 299-303.
22. Hvarfner C, Hillarp A, Larsson J. Influence of factor V Leiden on the development of neovascularization secondary to central retinal vein occlusion. Br J Ophthalmol 2003; 87: 305-6.
23. Kujovich JL. Factor Leiden thrombophilia. Gene Review 2004; 191: 412-24.